NEW YORK (360Dx) – NuView Life Sciences is preparing to launch a second phase of clinical trials of its NV-VPAC1 in vitro diagnostic test for detecting shed prostate cancer in voided urine.

The trials, scheduled to begin this fall, will include 1,500 patients and are intended at gathering additional data in preparation of a submission next year to the US Food and Drug Administration for clearance of the test .

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.